Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide.
Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology.
The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 5, 24 | -2.41 Increased by +27.84% | -2.77 Increased by +13.00% |
| Mar 11, 24 | -3.53 Increased by +17.72% | -3.96 Increased by +10.86% |
| Nov 9, 23 | -1.20 Increased by +77.74% | -3.11 Increased by +61.41% |
| Aug 2, 23 | -3.64 Increased by +34.88% | -2.81 Decreased by -29.54% |
| May 4, 23 | -3.34 Increased by +21.23% | -3.77 Increased by +11.41% |
| Feb 27, 23 | -4.29 Increased by +30.36% | -4.16 Decreased by -3.12% |
| Nov 9, 22 | -5.39 Decreased by -20.85% | -3.91 Decreased by -37.85% |
| Aug 8, 22 | -5.59 Decreased by -6.88% | -4.88 Decreased by -14.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 781.31 M Increased by +101.56% | 215.41 M Increased by +138.64% | Increased by +27.57% Increased by +119.17% |
| Jun 30, 23 | 595.26 M Increased by +74.27% | -381.14 M Increased by +33.30% | Decreased by -64.03% Increased by +61.73% |
| Mar 31, 23 | 447.80 M Increased by +46.04% | -348.43 M Increased by +19.77% | Decreased by -77.81% Increased by +45.06% |
| Dec 31, 22 | 380.10 M Increased by +77.63% | -445.33 M Increased by +23.96% | Decreased by -117.16% Increased by +57.19% |
| Sep 30, 22 | 387.63 M Increased by +87.77% | -557.56 M Decreased by -34.72% | Decreased by -143.84% Increased by +28.25% |
| Jun 30, 22 | 341.57 M Increased by +127.73% | -571.45 M Decreased by -18.97% | Decreased by -167.30% Increased by +47.76% |
| Mar 31, 22 | 306.63 M Decreased by -49.39% | -434.27 M Decreased by -753.09% | Decreased by -141.63% Decreased by -1.39 K% |
| Dec 31, 21 | 213.98 M Increased by +113.77% | -585.65 M Decreased by -23.88% | Decreased by -273.70% Increased by +42.05% |